Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.30 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315726 | 1.00 | SLC2A1 (0.34) | SLC2A1KMT2AHTR7ALDH1A1MEN1 | |
| SCHEMBL14135073 | 1.00 | SLC2A1 (0.34) | SLC2A1KMT2AHTR7ALDH1A1MEN1 | |
| SCHEMBL6963834 | 0.93 | SLC2A1 (0.37) | SLC2A1KMT2AHTR7ALDH1A1MEN1 | |
| SCHEMBL13519625 | 0.92 | HTR7 (0.34) | KMT2AHTR7ALDH1A1MCHR1HTR1A | |
| SCHEMBL2318639 | 0.92 | HTR7 (0.34) | KMT2AHTR7ALDH1A1MCHR1HTR1A | |
| Hydrochloric Acid SCHEMBL914555 | 0.92 | SLC2A1 (0.37) | SLC2A1KMT2AHTR7ALDH1A1MEN1 | |
| SCHEMBL2315691 | 0.91 | — | — | |
| SCHEMBL14135216 | 0.90 | KMT2A (0.38) | KMT2AALDH1A1MEN1MAPTDRD2 | |
| SCHEMBL12432834 | 0.90 | KMT2A (0.38) | KMT2AALDH1A1MEN1MAPTDRD2 | |
| SCHEMBL2316234 | 0.90 | KMT2A (0.38) | KMT2AALDH1A1MEN1MAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| EP-2125782-B1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | SLC2A1 803/4885KMT2A 1346/4885HTR7 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.